Literature DB >> 15629765

Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing.

Sid Gilman1, Robert A Koeppe, Roderick Little, Hyonggin An, Larry Junck, Bruno Giordani, Carol Persad, Mary Heumann, Kris Wernette.   

Abstract

We compared the relative utility of neuropsychological testing and positron emission tomography (PET) with [18F]fluorodeoxyglucose ([18F]FDG) in differentiating Alzheimer's disease (AD) from dementia with Lewy bodies (DLB). We studied 25 patients with AD, 20 with DLB, and 19 normal elderly controls. There was no difference between patient groups for MMSE, confrontational naming, or verbal learning. The DLB group was significantly more impaired than the AD group for verbal fluency, and the AD group was significantly more impaired than the DLB group for verbal delayed recall. The DLB group had greater difficulty than the AD group on a visual discrimination task that does not require motor functioning, but the difference did not reach significance. Family ratings of motor functioning suggested significantly greater impairment in DLB patients than in AD patients. PET studies revealed significantly lower local cerebral metabolic rates for glucose (lCMRglc) for visual cortex (Brodmann areas 17, 18, and 19) in the DLB than the AD group, but no differences for other regions commonly affected in AD, including posterior cingulate, superior parietal lobe, lateral temporal lobe, and the prefrontal region. Motor ratings were significantly correlated with lCMRglc in all areas of cerebral cortex, including Brodmann areas 17, 18, and 19. The results demonstrate a similar profile of cerebral hypometabolism in the two patient groups except in the visual cortex, where the DLB group shows markedly lower lCMRglc than the AD group. Neuropsychological testing also differentiates the groups, and family ratings of motor functioning are as robust as PET in these later stages of the disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15629765     DOI: 10.1016/j.expneurol.2004.06.017

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  26 in total

Review 1.  Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.

Authors:  Peter J Nestor; Daniele Altomare; Cristina Festari; Alexander Drzezga; Jasmine Rivolta; Zuzana Walker; Femke Bouwman; Stefania Orini; Ian Law; Federica Agosta; Javier Arbizu; Marina Boccardi; Flavio Nobili; Giovanni Battista Frisoni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-07       Impact factor: 9.236

2.  Motion discrimination in dementia with Lewy bodies and Alzheimer disease.

Authors:  Kelly M Landy; David P Salmon; Douglas Galasko; J Vincent Filoteo; Elena K Festa; William C Heindel; Lawrence A Hansen; Joanne M Hamilton
Journal:  Neurology       Date:  2015-09-23       Impact factor: 9.910

3.  Bringing functional brain image analysis to the clinician: initial assessment of an online interactive diagnostic aide.

Authors:  Kristin R Munch; John V Carlis; Jose V Pardo; Joel T Lee
Journal:  Comput Biol Med       Date:  2007-11-19       Impact factor: 4.589

Review 4.  Neuroimaging in Dementia.

Authors:  Adam M Staffaroni; Fanny M Elahi; Dana McDermott; Kacey Marton; Elissaios Karageorgiou; Simone Sacco; Matteo Paoletti; Eduardo Caverzasi; Christopher P Hess; Howard J Rosen; Michael D Geschwind
Journal:  Semin Neurol       Date:  2017-12-05       Impact factor: 3.420

Review 5.  Cognitive impairment and dementia in basal ganglia disorders.

Authors:  Julie C Stout; Shannon A Johnson
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

Review 6.  The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 2.

Authors:  T C Booth; M Nathan; A D Waldman; A-M Quigley; A H Schapira; J Buscombe
Journal:  AJNR Am J Neuroradiol       Date:  2014-06-12       Impact factor: 3.825

Review 7.  Neuroimaging biomarkers of neurodegenerative diseases and dementia.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

8.  18F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies.

Authors:  Jennifer L Whitwell; Jonathan Graff-Radford; Tarun D Singh; Daniel A Drubach; Matthew L Senjem; Anthony J Spychalla; Nirubol Tosakulwong; Val J Lowe; Keith A Josephs
Journal:  J Nucl Med       Date:  2016-09-29       Impact factor: 10.057

Review 9.  [Neurobiological early diagnosis of Alzheimer's disease].

Authors:  H Hampel; S J Teipel; K Bürger
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

10.  Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study.

Authors:  Peter K Panegyres; Jeffrey M Rogers; Michael McCarthy; Andrew Campbell; Jing Shan Wu
Journal:  BMC Neurol       Date:  2009-08-12       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.